Moderna to present mid-stage results on personalized cancer vaccine in April
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) on Tuesday said it would present mid-stage data on its investigational mRNA personalized cancer vaccine at an upcoming meeting in April.
The company said two abstracts on its mRNA-4157 vaccine had been accepted for presentation at the annual meeting of the American Association of Cancer Research (AACR) which will be held from April 14 to 19.

The news comes a day after Cowen analyst Tyler Van Buren issued positive views on the upcoming data for the cancer vaccine and also on its flu vaccine, and upgraded the stock's rating.
Given declining sales from its COVID-19 vaccine, MRNA is now counting on further mRNA vaccines it is developing to boost revenue.
The company said one of the abstracts would present mid-stage results on the efficacy and safety of mRNA-4157 combined with pembrolizumab versus pembrolizumab alone in patients with resected high-risk melanoma, the most serious type of skin cancer.
mRNA-4157 is being jointly developed by Moderna (MRNA) and Merck (MRK).